Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) on Tuesday, plunged -7.58% from the previous trading day, before settling in for the closing price of $37.46. Within the past 52 weeks, CRNX’s price has moved between $34.07 and $62.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 81.04%. The company achieved an average annual earnings per share of 0.22%. With a float of $86.57 million, this company’s outstanding shares have now reached $92.74 million.
Let’s determine the extent of company efficiency that accounts for 290 employees. In terms of profitability, gross margin is -43.31%, operating margin of -29586.81%, and the pretax margin is -26747.83%.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Crinetics Pharmaceuticals Inc is 6.65%, while institutional ownership is 104.00%. The most recent insider transaction that took place on Feb 03 ’25, was worth 195,350. In this transaction Chief Med and Dev Officer of this company sold 5,000 shares at a rate of $39.07, taking the stock ownership to the 31,748 shares. Before that another transaction happened on Feb 03 ’25, when Company’s Officer proposed sale 5,000 for $39.07, making the entire transaction worth $195,372.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.45% during the next five years compared to -10.59% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Crinetics Pharmaceuticals Inc (CRNX) is currently performing well based on its current performance indicators. A quick ratio of 16.38 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.72, a number that is poised to hit -0.89 in the next quarter and is forecasted to reach -3.78 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Looking closely at Crinetics Pharmaceuticals Inc (NASDAQ: CRNX), its last 5-days average volume was 0.83 million, which is a drop from its year-to-date volume of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 55.48%. Additionally, its Average True Range was 1.80.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 1.93%, which indicates a significant decrease from 8.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.07% in the past 14 days, which was lower than the 52.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.87, while its 200-day Moving Average is $50.01. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $36.83. Second resistance stands at $39.05. The third major resistance level sits at $40.42. If the price goes on to break the first support level at $33.25, it is likely to go to the next support level at $31.88. Now, if the price goes above the second support level, the third support stands at $29.66.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
Market capitalization of the company is 3.21 billion based on 92,738K outstanding shares. Right now, sales total 4,010 K and income totals -214,530 K. The company made 400 K in profit during its latest quarter, and -74,050 K in sales during its previous quarter.
